Reviva Pharmaceuticals Holdings Inc (RVPHW)

Reviva Pharmaceuticals Holdings Inc. (RVIV): A Deep Dive

Company Profile:

• 2008: Founded by Dr. Laxma Reddy and headquartered in Cranbury, NJ.
• Focus: Clinical stage pharmaceutical company specializing in developing therapies for various conditions.
• Corporate structure: Operates through subsidiaries;
• 2010: IPO on NASDAQ.
• Current CEO: Praveen Tyle, with over 30 years experience in pharmaceutical industry.

Top Products & Market Share:

• Main Products:

  • Investigational BRP-CS, an oral formulation for treating Acute Respiratory Distress Syndrome (ARDS).
  • Brilaroxazine: Investigational treatment of Chronic Cough and Prader-Willi Syndrome (PWS).

• Market Share:

  • ARDS: New drug, no market share yet.
  • Chronic cough: Estimated 250 million people globally, high unmet need, no current market share.
  • PWS market estimated at $2 billion, RVIV has exclusive global license to potential treatment (brilaroxazine).

• Competitive Landscape:

  • ARDS: Several large pharma companies developing treatments.
  • Brilaroxazine: Competing against existing therapies for cough and PWS, but with potential differentiation.

Total Addressable Market:

• ARDS market anticipated to reach $2.6 billion by 2030.
• Chronic cough: Large potential market with high unmet need.
• Prader-Will Syndrome: Market estimated at $2 billion.

Financial Performance:

• Recent Financial Statements:

  • 2023 Q2 Revenue: $2.27 million.
  • Net loss: $8.34 million.
  • Operating Expenses: $20 million.

• Year-over-Year:

  • Revenue decrease of 6.3%.
  • Operating expenses increase of 2.8%

• Cash Flow & Balance sheet:

  • Cash & Equivalents as of June 2023: $20.44 Million

Dividends and Shareholder Return:

• No current dividend payout.
  • Since IPO, stock price relatively flat, indicating low shareholder return.

Growth Trajectory:

• Historical Growth:

  Limited revenue generation so far, focusing on clinical development.

• Future Projections:

  • Potential approval for BRP-CS for ARDS.
  • Brilaroxazine has Phase 2 FDA clearance for Chronic Cough and is in Phase 2 clinical trial for Prader-Will syndrome, if successful could be significant revenue drivers.

Key Market Dynamics

• Industry Trends:

  • Growing need for innovative treatments for ARDS, chronic cough and rare diseases like PWS.
  • Focus on developing safer and more effective therapies with less side effects.

• Reviva's Positioning:

  • Strong pipeline of potential therapies, including orphan drug development, which could offer significant market advantage.

Key Competitors

| GlaxoSmithKline (GSK)| Respiratory therapies | Leading ARDS drug developer | | Roche (RHHBY) | Respiratory and rare disease treatments | Leading player in both markets | | Pfizer (PFE)| Large portfolio, including respiratory and rare diseases Leader in several therapeutic areas
| Ovid Therapeutics (OVID)| Prader Willi Syndrome treatments Developing different treatment approach |

Potential Challenges and Opportunities:

• Challenges:

  • Regulatory approval challenges for new drugs.
  • Competition in ARDS, Chronic Cough and PWS treatment markets.
  • Limited current revenue generation.

• Potential Opportunities:

  • Success in clinical trials and regulatory approval for BRP-CS and Brilaroxazine could significantly boost revenue.
  • Orphan drug designation for some therapies could offer market exclusivity.
  • Strategic partnerships for development and commercialization of treatments.

**Recent Acquisitions: **

• No significant acquisitions in the past 3 years.

AI Based Fundamental Rating:

• Overall Rating: 3.0 out of 10
  • Justification: While RVIV has promising pipeline and potential market opportunities, its lack of revenue, high operating expenses and competition raise concerns. Approval of its lead drug candidates could significantly change the outlook.

Sources:

• Reviva Pharmaceuticals website:
  www.revivapharma.com/
• SEC filings:
  www.sec.gov/edgar/search/#/company?company=reviva+pharmaceuticals+holdings%2c+inc.

Disclaimer: This analysis should not be considered as financial investment advice. Please consult a qualified professional for investment decisions.